Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8189 TQT Study in Schizophrenia
NCT05893862Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elpipodect in schizophrenia (6 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following MK-8189 Treatment at Day 2, Number of Participants With Adverse Events (AEs) and 1 more. Started Jun 2023; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05893862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893862.